NCT07648251Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Furosemide Oral Versus Placebo for Reduction of Hospital Length of Stay in Postpartum Women With Severe Preeclampsia: A Double-Blind, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (estimated)
- First submitted
- 9 Jun 2026
- Start date
- 15 Jun 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Universidad Nacional Autonoma de Honduras
- Diseases
- High blood pressure
- NCT number
- NCT07648251
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 186
- From 15 Jun 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnancy (current - not applicable postpartum, but excludes undiagnosed concurrent pregnancy)
Other illness
- Known allergy to sulfonamides or furosemide
- Active febrile illness
Lab values
- Known chronic kidney disease (eGFR \<60 mL/min/1.73m²)
Other
- Current or chronic diuretic use (before or during pregnancy)
- Participation in another interventional trial
Who the study is looking for
- Signed informed consent (assent for minors 14-17 years with parental/guardian consent)
- Confirmed severe preeclampsia (BP ≥160/110 mmHg, or lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral/visual symptoms)
- Postpartum (12-24 hours after delivery, vaginal or cesarean)
- Hemodynamically stable (no vasopressors for ≥6 hours)
- Preserved diuresis (\>30 mL/hour for ≥6 hours)
- Serum creatinine \<0.8 mg/dL
Age in the registry: 14 years to 49 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Escuela Coordinator of this site? Confirm its status | Tegucigalpa | Honduras | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.